Ibrahim Turfanda

Company: Eli Lilly & Company

Job title: Senior Director, Next Generation Incretins, NILEX & Outcomes

Seminars:

Panel Discussion: Discussing the Future Indications of GLP-1-Based Therapeutics – Promises & Challenges 2:30 pm

Advancing the reach of GLP-1-based treatments into other therapeutic areas, particularly Alzheimer’s and Parkinson’s disease Exploring the scientific validity of the latest treatment frontiers with GLP-1s to understand the potential in these areas Considering the commercial possibilities of these new therapeutic area markets to grasp the scope of opportunityRead more

day: Conference Day One

Exploring Current Evidence to Support the Expansion of GLP-1s into Renal Indications 1:30 pm

Exploring the reasons behind the potential benefits of GLP-1s in this therapeutic domain, and assessing the necessity of creating novel treatments for renal diseases Examining the supporting evidence for GLP-1s in renal indications to conclude their effectiveness in this patient population Deliberating on challenges and future strategies to extend the application of GLP-1 therapies into…Read more

day: Conference Day One

Unlocking Cardiovascular Potential: Presenting the Latest Evidence Supporting Positive Outcomes with GLP-1s 9:00 am

Exploring evidence supporting positive cardiovascular outcomes of GLP-1s to reveal the possibility of a cardiovascular market for therapies Considering approaches, including the use of agonist combinations, to gain positive cardiovascular outcomes Navigating potential challenges that may arise in the context of employing GLP-1 treatments for cardiovascular indicationsRead more

day: Conference Day One